Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)
This is a prospective, open-label, randomized controlled clinical trial designed to evaluate rabies virus neutralizing antibody responses to rabies vaccination among patients infected with human immunodeficiency virus (HIV). Eligible participants will be divided into two groups according to baseline CD4+ T cell count before randomization. Within each group, participants will be randomly assigned to one of two different rabies vaccination regimens for simulated post-exposure prophylaxis. Blood samples will be collected before vaccination and at scheduled time points after vaccination. Rabies virus neutralizing antibody titers will be tested to assess the seroconversion rate and geometric mean concentration (GMC). Adverse events after vaccination will also be recorded.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This prospective, open-label, randomized controlled clinical trial will enroll HIV-infected patients aged 18-60 years who are receiving antiretroviral therapy (ART). A total of 160 eligible participants will be divided into two groups based on baseline CD4+ T cell count (<350 cells/mm³ vs. ≥350 cells/mm³) before randomization, with 80 subjects in each group. Within each group, participants will be randomized in a 1:1 ratio to receive freeze-dried human rabies vaccine (Vero cell) under the Zagreb regimen or the Essen regimen.
Serum samples will be collected at scheduled time points according to different vaccination regimens. For participants assigned to the Zagreb regimen, blood samples will be obtained on Day 0, Day 14, Day 35, and three months after completion of the full vaccination course. For participants assigned to the Essen regimen, blood samples will be collected on Day 0, Day 14, Day 28, Day 42, and three months after completion of the full vaccination course. Rabies virus neutralizing antibody titers will be measured for all collected serum samples, and seroconversion rate and GMC will be calculated to assess immune responses at each predefined time point.
Participants with rabies virus neutralizing antibody titers lower than 0.5 IU/mL at 14 days after completion of the full vaccination course will receive booster vaccination on Day 0 and Day 3. Blood samples will be collected 14 days after booster administration to measure rabies virus neutralizing antibody titers. Seroconversion rate and GMC will be calculated to evaluate immune responses after booster vaccination.
Adverse events will be monitored throughout the study. All immediate adverse events occurring within 30 minutes after each dose will be recorded. Solicited adverse events will be monitored for 7 days after each dose. Unsolicited adverse events will be monitored from day 8 to day 14 following each dose.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Li Tong
- Número de teléfono: +86 15811315908
- Correo electrónico: 14877107@qq.com
Ubicaciones de estudio
-
-
Guangxi
-
Nanning, Guangxi, Porcelana, 530028
- Reclutamiento
- Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
-
Contacto:
- Xiaoyu Meng
- Número de teléfono: 0771-2518766
- Correo electrónico: cdc@wsjkw.gxzf.gov.cn
-
Investigador principal:
- Jingxia Luo
-
Nanning, Guangxi, Porcelana, 530012
- Reclutamiento
- The Fourth People's Hospital of Nanning City
-
Contacto:
- Jun Zou
- Número de teléfono: 0771-5625823
- Correo electrónico: cdc@wsjkw.gxzf.gov.cn
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV-infected participants aged 18 to 60 years, able to provide valid identification.
- Normal liver and renal function confirmed by laboratory testing within 7 days prior to screening or on the day of screening.
- Receiving antiretroviral therapy (ART) for at least 6 months with a stable CD4+ T cell count ≥350 cells/mm³; or receiving ART for at least 6 months with a CD4+ T cell count <350 cells/mm³ and previously treated, well-controlled opportunistic infections (no clinical signs of active opportunistic infection, normal routine blood tests, and normal liver and renal test results).
- No active opportunistic infection or tumor, no history of drug allergy, and no other severe acute or chronic illnesses.
- Willing to participate in the study voluntarily and provide written informed consent.
- Participants are able to attend all scheduled visits as required by the protocol, with no plans for long term absence or relocation away from the study site.
- Axillary temperature ≤37.2℃ at screening.
Exclusion Criteria:
- History of rabies vaccination.
- History of receiving any blood, blood products or immunoglobulin within 3 months prior to the first vaccine dose, or plans to use these products within 1 month after the last vaccine dose.
- Receipt of immunosuppressive therapy within 3 months prior to enrollment, including continuous administration of systemic glucocorticoids (for 14 days or longer at a dose of ≥20 mg per day).
- Participating in another clinical trial (vaccine or drug) or planning to participate in another clinical trial during the course of this trial.
- Confirmed pregnancy (positive urine pregnancy test at enrollment), or women of childbearing potential planning to become pregnant within 2 months.
- History of allergy to any component of the study vaccine, including excipients and antibiotics.
- Presence of any acute disease, or chronic disease in active phase.
- History of serious adverse events following administration of other vaccines.
- Any condition that may interfere with study outcomes or study procedures, as assessed by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Zagreb regimen (CD4+ T cell count ≥350 cells/mm³)
Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7, and 1 dose on day 21, for a total of 4 doses. |
0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.
Otros nombres:
|
|
Experimental: Essen regimen (CD4+ T cell count ≥350 cells/mm³)
Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses. |
0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.
Otros nombres:
|
|
Experimental: Zagreb regimen (CD4+ T cell count <350 cells/mm³)
Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7 and 1 dose on day 21, for a total of 4 doses. |
0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.
Otros nombres:
|
|
Experimental: Essen regimen (CD4+ T cell count <350 cells/mm³)
Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses. |
0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course
Periodo de tiempo: 14 days after completion of the full vaccination course
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by the rapid fluorescent focus inhibition test (RFFIT). |
14 days after completion of the full vaccination course
|
|
Incidence of adverse events after vaccination
Periodo de tiempo: 30 minutes, 0-7 days, and 8-14 days after each vaccine dose
|
Incidence of immediate local and systemic adverse events recorded within 30 minutes after each vaccination; incidence of solicited local and systemic adverse events collected 0-7 days after each dose; incidence of unsolicited adverse events collected 8-14 days after each dose. Adverse events are defined as any untoward medical occurrence in a participant administered vaccine, not necessarily having a causal relationship with vaccination. |
30 minutes, 0-7 days, and 8-14 days after each vaccine dose
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose of vaccination
Periodo de tiempo: 14 days after the first dose of vaccination
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose vaccination among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT. |
14 days after the first dose of vaccination
|
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course
Periodo de tiempo: 90 days after completion of the full vaccination course
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT. |
90 days after completion of the full vaccination course
|
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies after booster vaccination
Periodo de tiempo: 14 days after booster vaccination
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies 14 days after booster vaccination, in participants who remain seronegative (titer <0.5 IU/mL) at 14 days after completion of the full vaccination course. Booster vaccination consists of 2 doses administered on day 0 and day 3 of the booster phase. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT. |
14 days after booster vaccination
|
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 within the Essen regimen group
Periodo de tiempo: Day 28 within the Essen vaccination regimen
|
Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 among HIV-infected participants who are seronegative at baseline (Day 0) and assigned to the Essen five dose regimen. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralising antibodies will be assessed by RFFIT. |
Day 28 within the Essen vaccination regimen
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Infecciones transmitidas por la sangre
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema inmunológico
- Infecciones
- Infecciones por virus de ARN
- Enfermedades virales
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Infecciones Mononegavirales
- Infecciones por rabdoviridae
- Infecciones por VIH
- Rabia
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Técnicas citológicas
- Productos biológicos
- Mezclas complejas
- Técnicas histológicas
- Vacunas
- Vacunas virales
- Preservación del tejido
- Preservación, biológica
- Técnicas de preparación histocitológica
- Cryopreservation
- Vacunas de rabia
- Freeze Drying
Otros números de identificación del estudio
Otros números de identificación del estudio
- CDB-RV-PM-2026001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .